Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...
Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ...
AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an impressions ...
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. EXTON, PA, June ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
StockStory.org on MSN
The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call
AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales ...
Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI ® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE, 1 and a 52-week maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback